Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $314 million, a 2% increase from Q4 2024 and a 1% increase from the previous quarter [13] - Full year 2025 total revenue was $1.185 billion, compared to $1.112 billion in 2024 [18] - Non-GAAP earnings per share for Q4 2025 was $0.40, down from $0.60 in Q4 2024 [15] - GAAP earnings per share for Q4 2025 was a loss of $0.05, compared to a profit of $0.34 in Q4 2024 [15] - Annual recurring revenue (ARR) exited Q4 2025 at $636 million, a 10% increase from the 2024 exit rate [8][17] Business Line Data and Key Metrics Changes - Product revenue for Q4 2025 was $180 million, a decrease of 1% compared to Q4 2024 [14] - Service revenue for Q4 2025 was $134 million, an increase of 8% from Q4 2024 [14] - Full year 2025 product revenue was $666 million, compared to $631 million in 2024 [19] - Full year 2025 service revenue was $519 million, compared to $482 million in 2024 [19] Market Data and Key Metrics Changes - The company reported strong demand for its point-of-care connected devices, particularly the XT10, which contributed to robust top-line performance [5] - Competitive wins included major health systems and government healthcare facilities, indicating a strong market presence [5][10] - The Department of Veterans Affairs selected Omnicell's solutions for medication management across their network [11] Company Strategy and Development Direction - The company aims to transform into an end-to-end medication management platform technology company, focusing on innovative solutions to improve customer experience [5][6] - Key growth pillars include expanding market presence, scaling recurring revenue, and accelerating the technology platform [6][8] - The Titan XT automated dispensing system was introduced to unify automation and intelligence in medication management [7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum coming out of 2025, driven by a commitment to autonomous medication management [11] - There is confidence in the potential multi-year product refresh opportunity with Titan XT, expected to drive future growth [12][13] - Management acknowledged potential uncertainties around regulations and tariffs but remains focused on long-term value creation [11] Other Important Information - The company ended 2025 with cash and cash equivalents totaling $197 million, down from $369 million in 2024, reflecting debt repayment and stock repurchase [15][16] - Non-GAAP EBITDA for Q4 2025 was $37 million, compared to $46 million in Q4 2024 [15] Q&A Session Summary Question: Can you provide insights on product booking expectations and the refresh cycle? - Management indicated a refresh cycle opportunity exceeding $2.5 billion, with expectations for a similar rollout over the next 8 years [36] Question: Will there be incremental investments in sales and marketing for the Titan cycle? - Management confirmed investments in the sales force and clinical education to capitalize on market opportunities [40][43] Question: What feedback have customers provided regarding the transition from XT Extend to Titan? - Customers with aging fleets are encouraged to transition to Titan XT, while those with XT Extend will still benefit from cloud capabilities [47] Question: How does the company plan to mitigate tariff costs affecting margins? - Management is exploring supply chain optimization and has implemented mitigation efforts to manage tariff impacts [51] Question: What is the expected impact of AI tools on the company's offerings? - Management believes AI will enhance supply chain operations, and the infrastructure of OmniSphere is designed to support AI applications [76][78]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $314 million, a 2% increase from Q4 2024 and a 1% increase from the previous quarter [14] - Full year 2025 total revenue reached $1.185 billion, compared to $1.112 billion in 2024 [19] - Non-GAAP gross margin for Q4 2025 was 43.2%, down from 47.4% in Q4 2024 [15] - GAAP earnings per share for Q4 2025 was a loss of $0.05, compared to a profit of $0.34 in Q4 2024 [16] - Full year 2025 non-GAAP earnings per share was $1.62, down from $1.71 in 2024 [20] Business Line Data and Key Metrics Changes - Q4 2025 product revenue was $180 million, a decrease of 1% compared to Q4 2024, while service revenue was $134 million, an increase of 8% from Q4 2024 [15] - Full year 2025 product revenue was $666 million, compared to $631 million in 2024, and service revenue was $519 million, compared to $482 million in 2024 [19] Market Data and Key Metrics Changes - Annual recurring revenue (ARR) exited Q4 2025 at $636 million, a 10% increase from the 2024 exit rate of $580 million [18] - Product bookings for full year 2025 were $535 million, above the midpoint of guidance [18] - Product backlog as of December 31, 2025, was $640 million, down 1% compared to the 2024 exit [18] Company Strategy and Development Direction - The company aims to expand its market presence, scale recurring revenue, and accelerate its technology platform [5] - The introduction of Titan XT is a key part of the strategy to unify automation and intelligence in medication management [6] - The company is focused on transitioning to an end-to-end medication management platform technology company [4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum coming out of 2025, driven by customer demand and the introduction of Titan XT [11] - There is some uncertainty regarding regulations and tariffs, but overall hospital fundamentals are strong [11] - The company anticipates continued growth in 2026, with guidance for total revenue between $1.215 billion and $1.255 billion [26] Other Important Information - The company reported a decrease in cash and cash equivalents to $197 million as of December 31, 2025, down from $369 million in 2024, primarily due to debt repayment and stock repurchase [16][17] - The company achieved HITRUST CSF i1 certification for its OmniSphere platform, demonstrating commitment to cybersecurity [9] Q&A Session Summary Question: Insights on product booking expectations and the Titan cycle - Management believes the refresh cycle opportunity exceeds $2.5 billion and expects a similar rollout over the next 8 years [36][37] Question: Incremental investments around sales force and marketing - Management confirmed investments in the sales force and clinical education to capitalize on market opportunities [41][44] Question: Feedback from customers on XT Extend and Titan - Customers with XT Extend can still access cloud capabilities, and the company is engaging all customers with paths to the cloud [48] Question: Mitigation of tariff costs impacting gross margins - Management is exploring ways to optimize the cost structure and manage supply chain effectively to improve margins [52] Question: Update on robotics and expectations for bookings - Robotics currently accounts for a small percentage of product revenue, with ongoing efforts to develop suitable solutions [83][84] Question: Performance of Enliven and 340B services - Enliven faces headwinds in the retail segment, while 340B remains a compelling part of the specialty business [86][87]